CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

pembrolizumab

Last Updated: December 10, 2020
Result type: Reports
Project Number: PC0236-000
Product Line: Reimbursement Review

Generic Name: pembrolizumab

Brand Name: Keytruda

Manufacturer: Merck Canada

Therapeutic Area: Classical Hodgkin lymphoma

Indications: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.

Manufacturer Requested Reimbursement Criteria1: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.

Submission Type: Initial

Tumour Type: Lymphoma

Project Status: Pending

Call for patient/clinician input open: December 10, 2020

Call for patient/clinician input closed: February 5, 2021

Anticipated Date: January 29, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback